CHAMPIGNON BRANDS INC. IS A RESEARCH-DRIVEN COMPANY SPECIALIZING IN THE FORMULATION AND MANUFACTURING OF NOVEL KETAMINE, ANAESTHETICS AND ADAPTOGENIC DELIVERY PLATFORMS FOR THE NUTRACEUTICAL AND PSYCHEDELIC MEDICINE INDUSTRIES. CSE: SHRM | FWB: 496 | OTC: SHRMF * Confidential. Not for external distribution.
D I S C L A I M E R Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) the expected development of the Company’s business, projects and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for the Company’s projects; (v) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (v) renewal of the Company’s current customer, supplier and other material agreements; and (vi) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward- looking statements. * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 2
A B O U T U S Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non- GMO and vegan certified. * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 3
M E A S U R E D P S I L O C Y B I N D O S A G E S S T U D I E S A T U N I V E R S I T Y O F M I A M I Tassili is focused on development of therapeutics for multiple pathological psychological diseases based on psychedelic and cannabis compounds. In partnership with a multidisciplinary team of scientists and physicians at the University of Miami, Tassili is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (mTBI) and/or 100% Owned Subsidiary posttraumatic stress disorder (PTSD). Presently, Tassili is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD; final results are expected in 2021. * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 4
P S I L O C Y B I N P A T E N T P O R T F O L I O Tassili has filed four provisional patents and in collaboration with university research institutes intends to demonstrate that the clinical and physiological effectiveness in PTSD and obsessive-compulsive disorder (OCD) are enhanced by timely measured dosages of psilocybin and cannabidiol, with superior clinical results measured by objective outcomes. 1. “Controlled Release Formulations of Psilocybe-derived Agents and Methods for Their Use” SerialNo.62/915,092 Filing Date: October 15, 2019 2. “Controlled Release Formulations of Psilocybe-derived Agents in Combination with Cannabis-derived Agents and Methods for Their Use” Serial No. 100% Owned Subsidiary 62/880,269 Filing Date: July 30, 2019 3. “Controlled Release Formulations of Multiple Active Pharmaceutical Agents” Serial No. 62/880,271 Filing Date: July 30, 2019 4. “Methods And Compositions For Treating Mild Traumatic Brain Injury With Post Traumatic Stress Disorder” Serial No. 62/924,434 Filing Date: October 22, 2019 * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 5
V E R T I C A L L Y I N T E G R A T E D C R A F T M U S H R O O M P R O D U C T I O N A N D R E S E A R C H Artisan Growers operates a craft mushroom cultivation facility, capable of producing an assortment of organic craft mushroom varietals, including Lion's Mane, Chaga, Reishi and Agaricus Blazei. Artisan Growers utilizes a variety of cultivation techniques and grow infrastructure to produce premium craft mushrooms. Champignon has apportioned and allocated a dedicated laboratory area within the existing Artisan Growers facility for specific research and development (R&D) activities and fungus profile analysis, with the objective of: Further investigating the integration of its mushroom extracts as an • alternative medicine delivery system; Formulating bioactive compounds extracted from plants/fungi; • 100% Owned Subsidiary Cultivating fungus varietals, which will include psilocybin, to be • commenced as soon as the company has determined the appropriate artisan-growers.com regulatory approvals have been received; Isolating and synthesizing of certain plant/fungus extracts. • * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 6
P S Y C H E D E L I C M E D I C I N E / I P F O R M U L A T I O N S P O R T F O L I O Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries. Novoformulations is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility, located in Quebec, Canada, and an accredited pharmacy in Ontario. Novoformulations is actively formulating, developing and commercializing bioavailable delivery platforms, including: Transdermal (topical); • 100% Owned Subsidiary Intranasal; • Sublingual; • novoformulations.com Novel oral and suppository. • Also based in Quebec, Novoformulations' manufacturing partner will process its novel delivery platforms and formulations into marketable end-products at its 40,000-square-foot GMP-certified, Health Canada-approved and Federal Drug Administration-approved manufacturing facility. * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 7
K E T A M I N E D E L I V E R Y P L A T F O R M S * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m C S E : S H R M 8
O U R B R A N D S V I T A L I T Y S U P E R T E A S Champignon’s mushroom-derived CPG portfolio includes our flagship brand, Vitality Superteas. Our Vitality Superteas’ SKUs are formulated with the goal of revolutionizing conventional organic tea through the infusion of a proprietary blend of artensial mushrooms with medicinal properties. We assembled a roster of health professionals and food scientists boasting expertise in the realms of nutrition, naturopathy, and biochemistry with the objective of combining the premium, organic tea blends with some of the world’s most powerful superfoods. Champignon’s CPG portfolio is inspired by sustainability and all of our products are organic, non-GMO and vegan certified. * Confidential. Not for external distribution. c h a m p i g n o n b r a n d s . c o m | v i t a l i t y s u p e r t e a s . c o m C S E : S H R M 9
Recommend
More recommend
